x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012914
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human TMEM49/VMP1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | VMP1 |
| UniProt No. | Q96GC9 |
| Gene ID | 81671 |
| Gene Description | Vacuole membrane protein 1 is a transmembrane protein localized to intracellular vacuoles that was originally described as a protein promoting vacuole formation in acinar cells associated with acute pancreatitis. Over-expression of VMP1 promotes vacuole formation and subsequent cell death. Additional research studies demonstrated that VMP1 expression might be induced by starvation or the mTOR inhibitor rapamycin, which triggers autophagy. VMP1 is targeted along with LC3 to autophagosome membranes. Knockdown of VMP1 can inhibit autophagosome formation. VMP1 interacts with beclin-1, a key autophagy protein that activates the class III PI3 kinase Vps34. VMP1 functions in the degradation and clearance of zymogen-containing vacuoles during experimentally induced pancreatitis. During vacuole degradation and clearance, VMP1 interacts with the ubiquitin protease USP9X, suggesting a possible functional link between the molecular machinery of autophagy and the ubiquitin pathway. Orthologs of VMP1 from C. elegans, Drosophila, and Dictyostelium, have been shown to play a role in membrane trafficking, organelle organization, and autophagy. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
